首页 > 最新文献
paperpass

Cardiovascular diabetology. Endocrinology reports最新文献

英文 中文
From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling. 从双重到五重激动作用的下一代药理学治疗肥胖和2型糖尿病:协同促肠促胰岛素和核受体信号。
Pub Date : 2026-06-26 DOI: 10.1186/s40842-026-00321-4
Gaetano Santulli

Receptor-targeted polypharmacology is emerging as a promising strategy for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. GLP-1-GIP-lanifibranor, a unimolecular conjugate combining GLP-1R/GIPR co-agonism with pan-PPAR activation, enables receptor-guided intracellular delivery of lanifibranor to incretin receptor-expressing cells while limiting systemic off-target exposure. In obese mouse models, the conjugate produced greater reductions in body weight, adiposity, food intake, and hyperglycemia than semaglutide, GLP-1-GIP co-agonism, or lanifibranor alone, while significantly improving insulin sensitivity. Mechanistic analyses demonstrated receptor-dependent delivery and identified PPARδ signaling as a principal mediator of glycemic improvement independent of weight loss. Unlike unconjugated lanifibranor, the conjugate did not induce anemia, fluid retention, renal dysfunction, or adipocyte differentiation, supporting the concept that tissue-restricted PPAR activation may mitigate classical adverse effects of systemic PPAR agonism. These findings establish peptide-directed nuclear receptor targeting as a potentially important platform for next-generation metabolic therapeutics, although substantial translational uncertainties remain regarding clinical efficacy, safety, and long-term applicability.

受体靶向多药理学正在成为治疗肥胖、2型糖尿病和代谢功能障碍相关脂肪性肝炎的一种有前景的策略。GLP-1-GIP-lanifibranor是一种单分子偶联物,结合了GLP-1R/GIPR共激动作用和pan-PPAR激活,可以在受体引导下将lanifibranor传递到表达肠促胰岛素受体的细胞中,同时限制全身脱靶暴露。在肥胖小鼠模型中,与semaglutide、GLP-1-GIP共激动剂或lanifbranor单独相比,该缀合物在体重、肥胖、食物摄入和高血糖方面产生了更大的降低,同时显著改善了胰岛素敏感性。机制分析表明受体依赖性传递,并确定PPARδ信号是独立于体重减轻的血糖改善的主要介质。与未偶联的lanifbranor不同,该偶联物不会引起贫血、液体潴存、肾功能障碍或脂肪细胞分化,这支持了组织限制性PPAR激活可能减轻全身PPAR激动作用的经典不良反应的概念。这些发现确立了肽导向核受体靶向作为下一代代谢治疗的潜在重要平台,尽管在临床疗效、安全性和长期适用性方面仍存在大量的翻译不确定性。
{"title":"From dual to quintuple agonism for next-generation pharmacology to treat obesity and type 2 diabetes: synergistic incretin and nuclear receptor signaling.","authors":"Gaetano Santulli","doi":"10.1186/s40842-026-00321-4","DOIUrl":"10.1186/s40842-026-00321-4","url":null,"abstract":"<p><p>Receptor-targeted polypharmacology is emerging as a promising strategy for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis. GLP-1-GIP-lanifibranor, a unimolecular conjugate combining GLP-1R/GIPR co-agonism with pan-PPAR activation, enables receptor-guided intracellular delivery of lanifibranor to incretin receptor-expressing cells while limiting systemic off-target exposure. In obese mouse models, the conjugate produced greater reductions in body weight, adiposity, food intake, and hyperglycemia than semaglutide, GLP-1-GIP co-agonism, or lanifibranor alone, while significantly improving insulin sensitivity. Mechanistic analyses demonstrated receptor-dependent delivery and identified PPARδ signaling as a principal mediator of glycemic improvement independent of weight loss. Unlike unconjugated lanifibranor, the conjugate did not induce anemia, fluid retention, renal dysfunction, or adipocyte differentiation, supporting the concept that tissue-restricted PPAR activation may mitigate classical adverse effects of systemic PPAR agonism. These findings establish peptide-directed nuclear receptor targeting as a potentially important platform for next-generation metabolic therapeutics, although substantial translational uncertainties remain regarding clinical efficacy, safety, and long-term applicability.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13308489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148335681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis. SGLT2抑制剂对A期和B期心力衰竭合并2型糖尿病患者心脏结构和功能的影响:系统回顾和荟萃分析
Pub Date : 2026-06-23 DOI: 10.1186/s40842-026-00306-3
Vishwani Khanna, Aarushi Batra, Ashok Kumar, Samragyi Juneja, Abhishek Pandeya

Background: Stage A and B heart failure (HF) in type 2 diabetes (T2DM) represents a critical window for prevention. Although SGLT2 inhibitors (SGLT2i) are recommended for early HF risk reduction, their direct structural effects on pre-symptomatic myocardium remain insufficiently characterized in this population.

Methods: MEDLINE, Cochrane Central, Scopus, and ClinicalTrials.gov were searched from inception to February 2026 for studies comparing SGLT2i with placebo in T2DM with Stage A and B HF. Risk of bias was assessed with RoB 2.0. R (version4.5.2) was used to analyse outcomes. Certainty of evidence was assessed using GRADE.

Results: Ten trials (n = 773) showed significant reductions in LV mass (-3.37 g), LVMI (-1.84 g/m²) and E/e' (-0.81). SGLT2i improved weight, BMI, HbA1c, and systolic blood pressure. Safety outcomes were favorable, with no diabetic ketoacidosis reported.

Conclusions: SGLT2i use was associated with a significant reduction in LV mass and improvements in filling pressures, suggesting a favorable modification of underlying myocardium in Stage A and B HF. These changes likely reflect hemodynamic unloading and mass regression rather than immediate functional recovery.

背景:2型糖尿病(T2DM)的A期和B期心力衰竭(HF)是预防的关键窗口期。尽管SGLT2抑制剂(SGLT2i)被推荐用于早期HF风险降低,但其对症状前心肌的直接结构影响在这一人群中仍未充分表征。方法:检索MEDLINE、Cochrane Central、Scopus和ClinicalTrials.gov从成立到2026年2月的研究,比较SGLT2i与安慰剂对合并A期和B期HF的T2DM患者的影响。偏倚风险采用rob2.0进行评估。使用R (version4.5.2)分析结果。使用GRADE评估证据的确定性。结果:10项试验(n = 773)显示左室质量(-3.37 g)、LVMI (-1.84 g/m²)和E/ E′(-0.81)显著降低。SGLT2i可改善体重、BMI、HbA1c和收缩压。安全性结果良好,无糖尿病酮症酸中毒报告。结论:SGLT2i的使用与左室质量的显著降低和充盈压力的改善相关,表明对a期和B期心衰的潜在心肌有有利的改善。这些变化可能反映了血流动力学卸载和质量回归,而不是立即功能恢复。
{"title":"Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis.","authors":"Vishwani Khanna, Aarushi Batra, Ashok Kumar, Samragyi Juneja, Abhishek Pandeya","doi":"10.1186/s40842-026-00306-3","DOIUrl":"10.1186/s40842-026-00306-3","url":null,"abstract":"<p><strong>Background: </strong>Stage A and B heart failure (HF) in type 2 diabetes (T2DM) represents a critical window for prevention. Although SGLT2 inhibitors (SGLT2i) are recommended for early HF risk reduction, their direct structural effects on pre-symptomatic myocardium remain insufficiently characterized in this population.</p><p><strong>Methods: </strong>MEDLINE, Cochrane Central, Scopus, and ClinicalTrials.gov were searched from inception to February 2026 for studies comparing SGLT2i with placebo in T2DM with Stage A and B HF. Risk of bias was assessed with RoB 2.0. R (version4.5.2) was used to analyse outcomes. Certainty of evidence was assessed using GRADE.</p><p><strong>Results: </strong>Ten trials (n = 773) showed significant reductions in LV mass (-3.37 g), LVMI (-1.84 g/m²) and E/e' (-0.81). SGLT2i improved weight, BMI, HbA1c, and systolic blood pressure. Safety outcomes were favorable, with no diabetic ketoacidosis reported.</p><p><strong>Conclusions: </strong>SGLT2i use was associated with a significant reduction in LV mass and improvements in filling pressures, suggesting a favorable modification of underlying myocardium in Stage A and B HF. These changes likely reflect hemodynamic unloading and mass regression rather than immediate functional recovery.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13288799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148304552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals. 与GLP-1受体激动剂相关的肺部不良事件:呼吸安全信号的系统综述
Pub Date : 2026-06-19 DOI: 10.1186/s40842-026-00311-6
Aarushi Ahuja, Sai Prasad, Sahana Manoharan, Arya Sen, Richa Rana, Mansi Mody, Fnu Paras, Archita Archita, Sana Shaik, Kartik Mehta, Rachel Manoj, Prakashini Mishra, Subhi Mehta, Pulkit Kapoor
<p><strong>Background: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most rapidly growing drug classes in contemporary medicine, approved for type 2 diabetes mellitus (T2DM) and obesity management. Although gastrointestinal adverse effects are well characterised, the pulmonary safety profile of GLP-1 RAs remains incompletely defined, representing an important evidence gap given the scale of global prescribing.</p><p><strong>Objective: </strong>This systematic review aims to synthesise published evidence on respiratory adverse events temporally associated with GLP-1 RA therapy in adults, characterise their patterns and severity, appraise the risk of bias using validated design-appropriate tools, describe proposed pathophysiological mechanisms, and grade the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Given the heterogeneity of the included evidence-spanning case reports, pharmacovigilance analyses, and observational cohorts-this review is framed primarily as a signal-detection and evidence-mapping exercise rather than a causal-inference analysis.</p><p><strong>Eligibility criteria: </strong>Adults (≥ 18 years) receiving any approved GLP-1 RA for any indication. Eligible study designs included randomised controlled trials (RCTs), retrospective and prospective observational cohorts, pharmacovigilance disproportionality analyses, and case reports or series. Studies were excluded if they enrolled paediatric populations, involved animal or in vitro experiments, reported only metabolic or cardiovascular outcomes without respiratory adverse-event data, or were narrative reviews, editorials, or commentaries without primary data.</p><p><strong>Methods: </strong>A systematic review was conducted following PRISMA 2020 guidelines (PROSPERO: CRD420261305875). PubMed, Embase, and Scopus were searched from inception to January 2026. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs, the Newcastle-Ottawa Scale (NOS) for cohort studies, and Joanna Briggs Institute (JBI) checklists for case reports, case series, and pharmacovigilance studies. GRADE was applied at the outcome-domain level; evidence from uncontrolled designs (case reports, case series, pharmacovigilance analyses) was initially rated very low certainty, as these designs are inherently uncontrolled and start below the lowest GRADE tier. Given substantial heterogeneity, meta-analytic pooling was not performed; a pre-specified narrative synthesis following the Synthesis Without Meta-Analysis (SWiM) reporting guideline was conducted.</p><p><strong>Results: </strong>Nineteen studies met inclusion criteria: four RCTs (n = 1,884 participants), five retrospective cohort studies (n = 1,122,653 participants), three pharmacovigilance analyses (n = 498,892 spontaneous adverse-event reports), and seven case reports or case series (n = 13 patients). Spontaneous reports do not repre
背景:胰高血糖素样肽-1受体激动剂(GLP-1 RAs)是当代医学中发展最快的药物类别之一,已被批准用于2型糖尿病(T2DM)和肥胖治疗。尽管胃肠道不良反应已被很好地表征,但GLP-1 RAs的肺部安全性特征仍不完全确定,鉴于全球处方的规模,这是一个重要的证据缺口。目的:本系统综述旨在综合已发表的与成人GLP-1类风湿性关节炎治疗相关的呼吸不良事件的证据,描述其模式和严重程度,使用经过验证的设计适当工具评估偏倚风险,描述提出的病理生理机制,并使用分级建议评估、发展和评估(grade)框架对证据的确定性进行分级。考虑到纳入的证据跨越病例报告、药物警戒分析和观察队列的异质性,本综述主要是作为信号检测和证据绘制练习,而不是因果推理分析。资格标准:成人(≥18岁)接受任何批准的GLP-1 RA用于任何适应症。符合条件的研究设计包括随机对照试验(RCTs)、回顾性和前瞻性观察队列、药物警戒不相称性分析、病例报告或系列。如果研究纳入儿科人群,涉及动物或体外实验,仅报告代谢或心血管结果而没有呼吸不良事件数据,或者是没有原始数据的叙述性评论、社论或评论,则排除研究。方法:按照PRISMA 2020指南(PROSPERO: CRD420261305875)进行系统评价。PubMed, Embase和Scopus从成立到2026年1月进行了检索。对随机对照试验使用Cochrane偏倚风险2 (RoB2)工具,对队列研究使用纽卡斯尔-渥太华量表(NOS),对病例报告、病例系列和药物警戒研究使用Joanna Briggs研究所(JBI)清单进行偏倚风险评估。GRADE应用于结果域水平;来自非受控设计(病例报告、病例系列、药物警戒分析)的证据最初被评为非常低的确定性,因为这些设计本质上是不受控制的,开始时低于最低的GRADE级别。考虑到大量的异质性,没有进行荟萃分析合并;按照没有meta分析的综合(SWiM)报告指南进行预先指定的叙述综合。结果:19项研究符合纳入标准:4项随机对照试验(n = 1,884名受试者),5项回顾性队列研究(n = 1,122,653名受试者),3项药物警戒分析(n = 498,892例自发性不良事件报告),7例病例报告或病例系列(n = 13例患者)。自发报告不代表独特的暴露个体,也不与参与者计数汇总。偏倚风险:所有4项rct均被RoB2评为低风险(在3项试验中对开放标签结果的确定存在一些担忧,这是一个特定领域的问题,不会改变总体的RoB2类别);5个队列研究中有3个被NOS评为中度风险,1个被评为高风险(1个队列研究评级未报告,分类为未报告/无法评级);所有三项药物警戒研究均被JBI评为高风险;和病例报告被JBI评为方法上适当的,尽管这些工具不能克服单个病例设计固有的轶事性质和非常有限的通用性。上呼吸道感染(URTIs)是最常报告的不良事件(12项报告研究中有8项,66.7%),在所有随机对照试验中发生率与对照组相当(GRADE:中度确定性)。使用报告优势比(ROR 2.14, 95% CI 1.88-2.43; Cazzola 2024),药物警戒分析发现了呼吸困难和哮喘样事件的不成比例的报告信号,特别是艾塞那肽;这些信号只能产生假设,不能确定因果关系或发生率。据报道,与GLP-1 RA暴露相关的严重不良事件包括支气管痉挛过敏反应(n = 4例)、急性嗜酸性肺炎(n = 1例)、围手术期吸入性肺炎或肺炎(两个队列研究和一个病例系列中的多个围手术期病例)、急性呼吸窘迫综合征(ARDS; n = 2例,其中1例死亡需要体外膜氧合[ECMO])和自发性纵隔肺炎(n = 1)。一项大型全球回顾性队列研究(n = 331,863名匹配的患者;Henney 2024)表明,与二肽基肽酶-4 (DPP-4)抑制剂相比,GLP-1 RAs可显著降低肺炎发生率(风险比[HR] 0.60, 95%可信区间[CI] 0.58-0)。 62年;等级:低确定性);考虑到回顾性设计、活性和非惰性比较器以及残留混淆的可能性,这一发现应谨慎解释。严重呼吸事件的证据确定性非常低,这是由稀疏的病例报告和高风险药物警戒数据驱动的。结论:GLP-1类风湿性关节炎治疗具有呼吸安全性,根据机制、药物亚类和临床情况分层,既不完全是良性的,也不完全是危险的。常见上呼吸道症状较轻,与对照组相当。罕见但有临床后果的事件——包括过敏反应、嗜酸性肺炎、围手术期误吸和ards——已被报道与GLP-1 RA暴露有时间相关性,主要出现在病例报告和非常低确定性的药物警戒数据中;这些信号是假设产生的,不应被解释为确认的因果风险。基于exendin -4的药物(艾塞那肽和利昔那肽)似乎具有最高的超敏反应风险,可归因于其非人类结构来源。临床医生应保持对围手术期误吸风险的高度认识;应考虑个体化,延长手术前禁食间隔,以校准特定药物的药代动力学特征。从信号检测到因果推断,需要前瞻性、标准化和充分有力的研究,并预先指定呼吸终点。
{"title":"Pulmonary adverse events associated with GLP-1 receptor agonists: a systematic review of respiratory safety signals.","authors":"Aarushi Ahuja, Sai Prasad, Sahana Manoharan, Arya Sen, Richa Rana, Mansi Mody, Fnu Paras, Archita Archita, Sana Shaik, Kartik Mehta, Rachel Manoj, Prakashini Mishra, Subhi Mehta, Pulkit Kapoor","doi":"10.1186/s40842-026-00311-6","DOIUrl":"10.1186/s40842-026-00311-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most rapidly growing drug classes in contemporary medicine, approved for type 2 diabetes mellitus (T2DM) and obesity management. Although gastrointestinal adverse effects are well characterised, the pulmonary safety profile of GLP-1 RAs remains incompletely defined, representing an important evidence gap given the scale of global prescribing.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;This systematic review aims to synthesise published evidence on respiratory adverse events temporally associated with GLP-1 RA therapy in adults, characterise their patterns and severity, appraise the risk of bias using validated design-appropriate tools, describe proposed pathophysiological mechanisms, and grade the certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework. Given the heterogeneity of the included evidence-spanning case reports, pharmacovigilance analyses, and observational cohorts-this review is framed primarily as a signal-detection and evidence-mapping exercise rather than a causal-inference analysis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Eligibility criteria: &lt;/strong&gt;Adults (≥ 18 years) receiving any approved GLP-1 RA for any indication. Eligible study designs included randomised controlled trials (RCTs), retrospective and prospective observational cohorts, pharmacovigilance disproportionality analyses, and case reports or series. Studies were excluded if they enrolled paediatric populations, involved animal or in vitro experiments, reported only metabolic or cardiovascular outcomes without respiratory adverse-event data, or were narrative reviews, editorials, or commentaries without primary data.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A systematic review was conducted following PRISMA 2020 guidelines (PROSPERO: CRD420261305875). PubMed, Embase, and Scopus were searched from inception to January 2026. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB2) tool for RCTs, the Newcastle-Ottawa Scale (NOS) for cohort studies, and Joanna Briggs Institute (JBI) checklists for case reports, case series, and pharmacovigilance studies. GRADE was applied at the outcome-domain level; evidence from uncontrolled designs (case reports, case series, pharmacovigilance analyses) was initially rated very low certainty, as these designs are inherently uncontrolled and start below the lowest GRADE tier. Given substantial heterogeneity, meta-analytic pooling was not performed; a pre-specified narrative synthesis following the Synthesis Without Meta-Analysis (SWiM) reporting guideline was conducted.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Nineteen studies met inclusion criteria: four RCTs (n = 1,884 participants), five retrospective cohort studies (n = 1,122,653 participants), three pharmacovigilance analyses (n = 498,892 spontaneous adverse-event reports), and seven case reports or case series (n = 13 patients). Spontaneous reports do not repre","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13281493/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148280826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients. 非糖尿病患者SGLT2抑制对急性血管氧化还原的调节。
Pub Date : 2026-06-18 DOI: 10.1186/s40842-026-00304-5
Katica Cvitkusic Lukenda, Ana Cipak Gasparovic, Mirta Milic, Barbara Radovani, Frano Vuckovic, Jelena Jakab, Domagoj Vucic, Ana Kovacevic, Ivan Gudelj

Background: Coronary angiography induces oxidative stress through contrast media exposure and ionizing radiation, potentially contributing to vascular and renal injury. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exert antioxidant and anti-inflammatory effects beyond glycemic control. We investigated whether a single pre-procedural dose of empagliflozin modulates oxidative stress and inflammatory glycosylation patterns in non-diabetic patients undergoing elective coronary angiography.

Methods: In this prospective, randomized, double-blind study, 60 patients undergoing elective coronary angiography were assigned to standard care or empagliflozin 10 mg administered 2 h before the procedure. Blood samples were collected at baseline, 4 h, and 24 h post-procedure. Total antioxidant capacity (TAC), oxidative DNA damage (alkaline comet assay), and N-glycosylation profiles of immunoglobulin G (IgG) and total plasma proteins were analyzed. Longitudinal changes were assessed using mixed-effects models with correction for multiple testing.

Results: Baseline characteristics and procedural variables were comparable between groups. Empagliflozin administration was associated with attenuation of oxidative DNA damage 24 h after angiography and stabilization of antioxidant capacity compared with standard care. Directional shifts in IgG N-glycosylation toward a less pro-inflammatory profile were observed in the intervention group, including reduced agalactosylated and core-fucosylated glycans and relative preservation of galactosylated structures. Similar modulatory trends were detected in total plasma protein glycosylation patterns. Although several glycomic changes did not reach statistical significance after correction for multiple testing, the overall biological signal consistently favored reduced oxidative and inflammatory activation in the empagliflozin group.

Conclusions: A single pre-procedural dose of empagliflozin was associated with attenuation of oxidative stress-related DNA damage and modulation of inflammatory glycosylation patterns following coronary angiography. These findings suggest a potential peri-procedural cytoprotective role of SGLT2 inhibition that warrants confirmation in larger studies.

Trial registration: ISRCTN11022820. Registered 13 October 2025. Retrospectively registered.

背景:冠状动脉造影通过造影剂暴露和电离辐射诱导氧化应激,可能导致血管和肾脏损伤。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)除血糖控制外还具有抗氧化和抗炎作用。我们研究了单次术前剂量的恩格列清是否能调节非糖尿病患者择期接受冠状动脉造影的氧化应激和炎症糖基化模式。方法:在这项前瞻性、随机、双盲研究中,60名接受选择性冠状动脉造影的患者被分配到标准治疗组或术前2小时给予依格列清10mg。在基线、术后4小时和24小时采集血样。分析了总抗氧化能力(TAC)、氧化DNA损伤(碱性彗星试验)、免疫球蛋白G (IgG)和总血浆蛋白的n -糖基化谱。采用混合效应模型评估纵向变化,并对多重检验进行校正。结果:两组间基线特征和程序变量具有可比性。与标准护理相比,给予恩格列净与血管造影后24小时氧化DNA损伤的衰减和抗氧化能力的稳定有关。在干预组中,观察到IgG n -糖基化向较少促炎的方向转变,包括未半乳糖基化和核心集中的聚糖减少以及半乳糖基化结构的相对保存。在总血浆蛋白糖基化模式中检测到类似的调节趋势。虽然经过多次测试校正后,几项糖糖变化没有达到统计学意义,但在恩格列净组中,总体生物学信号一致倾向于氧化和炎症激活的降低。结论:单次术前剂量的恩格列净与冠状动脉造影后氧化应激相关DNA损伤的衰减和炎症糖基化模式的调节有关。这些发现表明SGLT2抑制具有潜在的程序性细胞保护作用,值得在更大规模的研究中证实。试验注册号:ISRCTN11022820。注册于2025年10月13日。回顾注册。
{"title":"Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients.","authors":"Katica Cvitkusic Lukenda, Ana Cipak Gasparovic, Mirta Milic, Barbara Radovani, Frano Vuckovic, Jelena Jakab, Domagoj Vucic, Ana Kovacevic, Ivan Gudelj","doi":"10.1186/s40842-026-00304-5","DOIUrl":"10.1186/s40842-026-00304-5","url":null,"abstract":"<p><strong>Background: </strong>Coronary angiography induces oxidative stress through contrast media exposure and ionizing radiation, potentially contributing to vascular and renal injury. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exert antioxidant and anti-inflammatory effects beyond glycemic control. We investigated whether a single pre-procedural dose of empagliflozin modulates oxidative stress and inflammatory glycosylation patterns in non-diabetic patients undergoing elective coronary angiography.</p><p><strong>Methods: </strong>In this prospective, randomized, double-blind study, 60 patients undergoing elective coronary angiography were assigned to standard care or empagliflozin 10 mg administered 2 h before the procedure. Blood samples were collected at baseline, 4 h, and 24 h post-procedure. Total antioxidant capacity (TAC), oxidative DNA damage (alkaline comet assay), and N-glycosylation profiles of immunoglobulin G (IgG) and total plasma proteins were analyzed. Longitudinal changes were assessed using mixed-effects models with correction for multiple testing.</p><p><strong>Results: </strong>Baseline characteristics and procedural variables were comparable between groups. Empagliflozin administration was associated with attenuation of oxidative DNA damage 24 h after angiography and stabilization of antioxidant capacity compared with standard care. Directional shifts in IgG N-glycosylation toward a less pro-inflammatory profile were observed in the intervention group, including reduced agalactosylated and core-fucosylated glycans and relative preservation of galactosylated structures. Similar modulatory trends were detected in total plasma protein glycosylation patterns. Although several glycomic changes did not reach statistical significance after correction for multiple testing, the overall biological signal consistently favored reduced oxidative and inflammatory activation in the empagliflozin group.</p><p><strong>Conclusions: </strong>A single pre-procedural dose of empagliflozin was associated with attenuation of oxidative stress-related DNA damage and modulation of inflammatory glycosylation patterns following coronary angiography. These findings suggest a potential peri-procedural cytoprotective role of SGLT2 inhibition that warrants confirmation in larger studies.</p><p><strong>Trial registration: </strong>ISRCTN11022820. Registered 13 October 2025. Retrospectively registered.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13277242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between the atherogenic index of plasma trajectory and risk of cardiovascular diseases among hypertensive patients: a prospective cohort study. 高血压患者血浆动脉粥样硬化指数与心血管疾病风险的相关性:一项前瞻性队列研究
Pub Date : 2026-06-12 DOI: 10.1186/s40842-026-00302-7
Weiqiang Wu, Peng Fu, Zefeng Cai, Yuxian Wang, Kuangyi Wu, Hong Zheng, Guanlin Chen, Zekai Chen, Yulong Lan, Yanjuan Chen, Shouling Wu, Youren Chen

Background: Cardiovascular disease (CVD) remains the leading cause of global mortality, with hypertension and dyslipidemia synergistically exacerbating the atherogenic risk. The atherogenic index of plasma (AIP), calculated as log (triglycerides/HDL-C), reflects lipid-driven atherosclerosis; however, evidence of long-term AIP trajectory patterns and their cardiovascular implications in hypertensive populations remains scarce.

Methods: This longitudinal study included 20,013 hypertensive participants (mean age: 56.8 ± 11.0 years; 81.9% male) from the Kailuan cohort, China. The AIP trajectories (2006-2010) were modeled using latent mixture modeling. Cox proportional hazards models were used to assess associations between AIP trajectories and incident CVD (2010-2020), adjusting for demographics, comorbidities, and medications.

Results: Four distinct AIP trajectories were identified: Low-stable group (n = 2,920; AIP range: -0.84 to -0.72), Moderate low-stable group (n = 11,121; AIP range: -0.14 to -0.10), Moderate high-stable group (n = 5,067; AIP range: 0.42 to 0.53), Elevated-increasing group (n = 905; AIP range: 1.12 to 1.46). Over a median of 11.9 (interquartile range 11.3-12.3) years of follow-up, 2,332 CVD events occurred. Compared with the low-stable group, participants in the elevated-increasing trajectory exhibited a 43% higher CVD risk (HR = 1.43, 95% CI:1.14-1.79; P-trend = 0.001), with significantly elevated risks of myocardial infarction (HR = 1.80, 1.09-2.51; P-trend < 0.001) and ischemic stroke (HR = 1.40, 1.08-1.80; P-trend = 0.001). Young hypertensives (< 45 years) with rising AIP trajectories demonstrated a 3.4-fold higher CVD risk (HR = 3.40, 1.03-11.16), whereas no associations were observed for hemorrhagic stroke (P-trend = 0.734).

Conclusions: Sustained elevation in AIP trajectories is associated with a higher risk of CVD in individuals with hypertension. Sustained maintenance of optimal AIP levels through regular monitoring, combined with blood pressure control and antihypertensive medication adherence, may reduce the CVD risk in hypertensive populations.

背景:心血管疾病(CVD)仍然是全球死亡的主要原因,高血压和血脂异常共同加剧了动脉粥样硬化的风险。血浆动脉粥样硬化指数(AIP),以log(甘油三酯/HDL-C)计算,反映脂质驱动的动脉粥样硬化;然而,长期AIP轨迹模式及其在高血压人群中的心血管影响的证据仍然很少。方法:这项纵向研究包括来自中国开滦队列的20,013名高血压患者(平均年龄:56.8±11.0岁,81.9%为男性)。采用潜在混合模型对2006-2010年AIP轨迹进行建模。Cox比例风险模型用于评估AIP轨迹与CVD事件(2010-2020)之间的关联,并对人口统计学、合并症和药物进行调整。结果:确定了4种不同的AIP轨迹:低稳定组(n = 2,920, AIP范围:-0.84 ~ -0.72),中等低稳定组(n = 11,121, AIP范围:-0.14 ~ -0.10),中等高稳定组(n = 5,067, AIP范围:0.42 ~ 0.53),升高组(n = 905, AIP范围:1.12 ~ 1.46)。在中位11.9年(四分位数范围11.3-12.3)的随访期间,发生了2332例CVD事件。与低稳定组相比,处于升高-升高轨道的参与者CVD风险高出43% (HR = 1.43, 95% CI:1.14-1.79; p趋势= 0.001),心肌梗死风险显著升高(HR = 1.80, 1.09-2.51; p趋势结论:高血压患者AIP轨迹持续升高与CVD风险升高相关。通过定期监测持续维持最佳AIP水平,结合血压控制和抗高血压药物依从性,可以降低高血压人群的心血管疾病风险。
{"title":"Association between the atherogenic index of plasma trajectory and risk of cardiovascular diseases among hypertensive patients: a prospective cohort study.","authors":"Weiqiang Wu, Peng Fu, Zefeng Cai, Yuxian Wang, Kuangyi Wu, Hong Zheng, Guanlin Chen, Zekai Chen, Yulong Lan, Yanjuan Chen, Shouling Wu, Youren Chen","doi":"10.1186/s40842-026-00302-7","DOIUrl":"10.1186/s40842-026-00302-7","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease (CVD) remains the leading cause of global mortality, with hypertension and dyslipidemia synergistically exacerbating the atherogenic risk. The atherogenic index of plasma (AIP), calculated as log (triglycerides/HDL-C), reflects lipid-driven atherosclerosis; however, evidence of long-term AIP trajectory patterns and their cardiovascular implications in hypertensive populations remains scarce.</p><p><strong>Methods: </strong>This longitudinal study included 20,013 hypertensive participants (mean age: 56.8 ± 11.0 years; 81.9% male) from the Kailuan cohort, China. The AIP trajectories (2006-2010) were modeled using latent mixture modeling. Cox proportional hazards models were used to assess associations between AIP trajectories and incident CVD (2010-2020), adjusting for demographics, comorbidities, and medications.</p><p><strong>Results: </strong>Four distinct AIP trajectories were identified: Low-stable group (n = 2,920; AIP range: -0.84 to -0.72), Moderate low-stable group (n = 11,121; AIP range: -0.14 to -0.10), Moderate high-stable group (n = 5,067; AIP range: 0.42 to 0.53), Elevated-increasing group (n = 905; AIP range: 1.12 to 1.46). Over a median of 11.9 (interquartile range 11.3-12.3) years of follow-up, 2,332 CVD events occurred. Compared with the low-stable group, participants in the elevated-increasing trajectory exhibited a 43% higher CVD risk (HR = 1.43, 95% CI:1.14-1.79; P-trend = 0.001), with significantly elevated risks of myocardial infarction (HR = 1.80, 1.09-2.51; P-trend < 0.001) and ischemic stroke (HR = 1.40, 1.08-1.80; P-trend = 0.001). Young hypertensives (< 45 years) with rising AIP trajectories demonstrated a 3.4-fold higher CVD risk (HR = 3.40, 1.03-11.16), whereas no associations were observed for hemorrhagic stroke (P-trend = 0.734).</p><p><strong>Conclusions: </strong>Sustained elevation in AIP trajectories is associated with a higher risk of CVD in individuals with hypertension. Sustained maintenance of optimal AIP levels through regular monitoring, combined with blood pressure control and antihypertensive medication adherence, may reduce the CVD risk in hypertensive populations.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13262429/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia: a systematic review and meta-analysis. 埃塞俄比亚非传染性疾病患者高尿酸血症患病率:系统回顾和荟萃分析
Pub Date : 2026-06-11 DOI: 10.1186/s40842-026-00301-8
Afewerk Habtamu, Zewudu Mulatie, Mikiyas Shemelis Achame, Sisay Desale, Saleamlak Sebsibe, Yonas Erkihun, Yeshimebet Kassa, Tesfaye Gessese, Mihreteab Alebachew, Mahider Shimelis Feyisa, Bruktawit Eshetu

Background: Hyperuricemia is one of the driving factors for the onset and progression of cardiovascular diseases, type 2 diabetes and hypertension. However, hyperuricemia is not measured regularly for these patients, and its worsening effect is underestimated. Thus, this systematic review and meta-analysis aimed to determine the pooled magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia.

Methods and materials: This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Bibliographic databases and gray literature were extensively searched for relevant articles. Eligible articles were extracted using Microsoft Excel and exported to STATA version 17 software for statistical analysis. The pooled magnitude of hyperuricemia computed with Random-effects model. Furthermore, Sensitivity and subgroup analysis was done. Heterogeneity was determined using the I2 value. Funnel plot and Egger's test statistics was used to assess publication bias.

Results: A total of 2292 patients from 8 studies were included in this systematic review and meta-analysis. The overall pooled prevalence of hyperuricemia among all patients with non-communicable diseases was 34.64% (95% CI: 29.27%, 40.02%). The prevalence of hyperuricemia among patients with cardiovascular diseases was 42.15% (95% CI: 38.08, 46.21), hypertension 34.79% (95% CI: 20.16, 49.42) and type 2 diabetes 30.87% (95% CI: 24.54, 37.20). The highest prevalence was found in Amhara region (36.73%, 95% CI: 26.12, 47.33), and the lowest was in Central Ethiopia (32.01%, 95% CI: 22.68, 41.34). The magnitude of hyperuricemia among females and males was 34.71% (95% CI: 27.79, 41.63) and 34.51% (95% CI: 29.91, 39.10) respectively. Hyperuricemia among participants aged < 45 years and > 45 years was 27.33% (95% CI: 19.82, 34.85) and 39.68% (95% CI: 34.08, 45.29) respectively.

Conclusion: This systematic review and meta-analysis showed high prevalence of hyperuricemia among patients with non-communicable diseases. Therefore, regular monitoring of uric acid level is required to prevent its pathophysiological role in patients with non-communicable diseases.

Systematic review registration: PROSPERO (2025: CRD420251174980).

背景:高尿酸血症是心血管疾病、2型糖尿病和高血压发生和发展的驱动因素之一。然而,这些患者没有定期测量高尿酸血症,其恶化效应被低估。因此,本系统综述和荟萃分析旨在确定埃塞俄比亚非传染性疾病患者高尿酸血症的总体程度。方法和材料:本系统评价和荟萃分析按照系统评价和荟萃分析指南的首选报告项目进行。在书目数据库和灰色文献中广泛搜索相关文章。使用Microsoft Excel提取符合条件的文章,导出到STATA version 17软件进行统计分析。用随机效应模型计算高尿酸血症的合并程度。并进行敏感性和亚组分析。采用I2值确定异质性。采用漏斗图和Egger检验统计量评估发表偏倚。结果:来自8项研究的2292例患者被纳入本系统评价和荟萃分析。所有非传染性疾病患者中高尿酸血症的总总患病率为34.64% (95% CI: 29.27%, 40.02%)。心血管疾病患者高尿酸血症患病率为42.15% (95% CI: 38.08 ~ 46.21),高血压患病率为34.79% (95% CI: 20.16 ~ 49.42), 2型糖尿病患病率为30.87% (95% CI: 24.54 ~ 37.20)。阿姆哈拉地区患病率最高(36.73%,95% CI: 26.12, 47.33),埃塞俄比亚中部患病率最低(32.01%,95% CI: 22.68, 41.34)。女性和男性高尿酸血症程度分别为34.71% (95% CI: 27.79, 41.63)和34.51% (95% CI: 29.91, 39.10)。45岁的高尿酸血症患者分别为27.33% (95% CI: 19.82, 34.85)和39.68% (95% CI: 34.08, 45.29)。结论:本系统综述和荟萃分析显示,非传染性疾病患者中高尿酸血症的患病率很高。因此,需要定期监测尿酸水平,以防止其在非传染性疾病患者中的病理生理作用。系统评价注册:PROSPERO (2025: CRD420251174980)。
{"title":"Prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia: a systematic review and meta-analysis.","authors":"Afewerk Habtamu, Zewudu Mulatie, Mikiyas Shemelis Achame, Sisay Desale, Saleamlak Sebsibe, Yonas Erkihun, Yeshimebet Kassa, Tesfaye Gessese, Mihreteab Alebachew, Mahider Shimelis Feyisa, Bruktawit Eshetu","doi":"10.1186/s40842-026-00301-8","DOIUrl":"10.1186/s40842-026-00301-8","url":null,"abstract":"<p><strong>Background: </strong>Hyperuricemia is one of the driving factors for the onset and progression of cardiovascular diseases, type 2 diabetes and hypertension. However, hyperuricemia is not measured regularly for these patients, and its worsening effect is underestimated. Thus, this systematic review and meta-analysis aimed to determine the pooled magnitude of hyperuricemia among patients with non-communicable diseases in Ethiopia.</p><p><strong>Methods and materials: </strong>This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Bibliographic databases and gray literature were extensively searched for relevant articles. Eligible articles were extracted using Microsoft Excel and exported to STATA version 17 software for statistical analysis. The pooled magnitude of hyperuricemia computed with Random-effects model. Furthermore, Sensitivity and subgroup analysis was done. Heterogeneity was determined using the I<sup>2</sup> value. Funnel plot and Egger's test statistics was used to assess publication bias.</p><p><strong>Results: </strong>A total of 2292 patients from 8 studies were included in this systematic review and meta-analysis. The overall pooled prevalence of hyperuricemia among all patients with non-communicable diseases was 34.64% (95% CI: 29.27%, 40.02%). The prevalence of hyperuricemia among patients with cardiovascular diseases was 42.15% (95% CI: 38.08, 46.21), hypertension 34.79% (95% CI: 20.16, 49.42) and type 2 diabetes 30.87% (95% CI: 24.54, 37.20). The highest prevalence was found in Amhara region (36.73%, 95% CI: 26.12, 47.33), and the lowest was in Central Ethiopia (32.01%, 95% CI: 22.68, 41.34). The magnitude of hyperuricemia among females and males was 34.71% (95% CI: 27.79, 41.63) and 34.51% (95% CI: 29.91, 39.10) respectively. Hyperuricemia among participants aged < 45 years and > 45 years was 27.33% (95% CI: 19.82, 34.85) and 39.68% (95% CI: 34.08, 45.29) respectively.</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis showed high prevalence of hyperuricemia among patients with non-communicable diseases. Therefore, regular monitoring of uric acid level is required to prevent its pathophysiological role in patients with non-communicable diseases.</p><p><strong>Systematic review registration: </strong>PROSPERO (2025: CRD420251174980).</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13255456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148221596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical characteristics and outcomes of diabetic ketoacidosis in patients with type 2 diabetes during acute systemic stress. 急性全身应激期2型糖尿病患者糖尿病酮症酸中毒的临床特点及结局。
Pub Date : 2026-06-08 DOI: 10.1186/s40842-026-00293-5
Rania Al Sayed Abd Albaky Mohamed, Laila Mahmoud Ali Hendawy, Eman Elsayed Mahmoud Farghaly, Amr Mahmoud Mohamed Abd El Hady Saleh

BACKGROUND: Many reports indicate that diabetes is one of the main risk factors for COVID-19 complications. Nevertheless, few studies have examined how DKA develops in T2DM patients who have SARS-CoV-2 infection. OBJECTIVES: This study aimed to assess β-cell function, identify risk factors for DKA, and evaluate clinical outcomes in hospitalized patients with T2DM and COVID-19. METHODS: A retrospective, single-center, case–control study was conducted at Ain Shams University Isolation Hospital from August 2021 to August 2022. The study included 70 adults with T2DM and confirmed COVID-19, categorized into two groups: 35 patients with DKA (cases) and 35 patients without DKA (controls). Clinical, laboratory, and outcome data were extracted from medical records. RESULTS: Fasting C-peptide levels did not differ significantly between the DKA and non-DKA groups (median difference: −0.06 ng/mL, 95% CI − 0.28 to 0.16; p = 0.363), suggesting that absolute insulin deficiency was not the primary driver of DKA in this cohort. The DKA group was significantly older (mean difference: 9.8 years, 95% CI 4.2 to 16.0; p = 0.003) and had a longer median diabetes duration (median difference: 3.7 years, 95% CI 1.3 to 6.1; p = 0.009). These patients also presented increased levels of inflammatory and stress markers, including D-dimer (mean difference: 0.21 ng/mL, 95% CI 0.05 to 0.37; p = 0.020) and HOMA-IR (median difference: 1.93, 95% CI 0.45 to 3.60; p = 0.012). Mortality was significantly greater in the DKA group (22.9% vs. 0%, risk difference 22.9%, 95% CI 8.4% to 37.4%; p = 0.003). CONCLUSION: In patients with T2DM and COVID-19, DKA was not characterized by absolute insulinopenia but was associated with older age, longer diabetes duration, severe insulin resistance, and systemic inflammation. These factors contribute to significantly increased morbidity and mortality. Our findings highlight the multifactorial nature of DKA in this setting and underscore the importance of aggressive monitoring and management in high-risk patients. CLINICAL TRIAL NUMBER : Not applicable.

背景:许多报告表明,糖尿病是COVID-19并发症的主要危险因素之一。然而,很少有研究调查了感染SARS-CoV-2的T2DM患者中DKA的发展情况。目的:本研究旨在评估T2DM合并COVID-19住院患者的β细胞功能,确定DKA的危险因素,并评估临床结局。方法:于2021年8月至2022年8月在艾因沙姆斯大学隔离医院进行回顾性、单中心、病例对照研究。该研究包括70名患有T2DM并确诊为COVID-19的成年人,分为两组:35名DKA患者(病例)和35名无DKA患者(对照组)。从医疗记录中提取临床、实验室和结局数据。结果:空腹c肽水平在DKA组和非DKA组之间没有显著差异(中位数差异:-0.06 ng/mL, 95% CI - 0.28至0.16;p = 0.363),表明绝对胰岛素缺乏不是该队列中DKA的主要驱动因素。DKA组明显更老(平均差值:9.8岁,95% CI 4.2 ~ 16.0; p = 0.003),糖尿病中位病程更长(中位差值:3.7年,95% CI 1.3 ~ 6.1; p = 0.009)。这些患者还表现出炎症和应激标志物水平升高,包括d -二聚体(平均差异:0.21 ng/mL, 95% CI 0.05至0.37;p = 0.020)和HOMA-IR(中位差异:1.93,95% CI 0.45至3.60;p = 0.012)。DKA组的死亡率明显更高(22.9%比0%,风险差22.9%,95% CI 8.4% ~ 37.4%; p = 0.003)。结论:在T2DM合并COVID-19患者中,DKA不以绝对胰岛素缺乏为特征,但与年龄较大、糖尿病病程较长、严重胰岛素抵抗和全身性炎症有关。这些因素导致发病率和死亡率显著增加。我们的研究结果强调了在这种情况下DKA的多因素性质,并强调了在高危患者中积极监测和管理的重要性。临床试验号:不适用。
{"title":"Clinical characteristics and outcomes of diabetic ketoacidosis in patients with type 2 diabetes during acute systemic stress.","authors":"Rania Al Sayed Abd Albaky Mohamed, Laila Mahmoud Ali Hendawy, Eman Elsayed Mahmoud Farghaly, Amr Mahmoud Mohamed Abd El Hady Saleh","doi":"10.1186/s40842-026-00293-5","DOIUrl":"10.1186/s40842-026-00293-5","url":null,"abstract":"<p><p>BACKGROUND: Many reports indicate that diabetes is one of the main risk factors for COVID-19 complications. Nevertheless, few studies have examined how DKA develops in T2DM patients who have SARS-CoV-2 infection. OBJECTIVES: This study aimed to assess β-cell function, identify risk factors for DKA, and evaluate clinical outcomes in hospitalized patients with T2DM and COVID-19. METHODS: A retrospective, single-center, case–control study was conducted at Ain Shams University Isolation Hospital from August 2021 to August 2022. The study included 70 adults with T2DM and confirmed COVID-19, categorized into two groups: 35 patients with DKA (cases) and 35 patients without DKA (controls). Clinical, laboratory, and outcome data were extracted from medical records. RESULTS: Fasting C-peptide levels did not differ significantly between the DKA and non-DKA groups (median difference: −0.06 ng/mL, 95% CI − 0.28 to 0.16; p = 0.363), suggesting that absolute insulin deficiency was not the primary driver of DKA in this cohort. The DKA group was significantly older (mean difference: 9.8 years, 95% CI 4.2 to 16.0; p = 0.003) and had a longer median diabetes duration (median difference: 3.7 years, 95% CI 1.3 to 6.1; p = 0.009). These patients also presented increased levels of inflammatory and stress markers, including D-dimer (mean difference: 0.21 ng/mL, 95% CI 0.05 to 0.37; p = 0.020) and HOMA-IR (median difference: 1.93, 95% CI 0.45 to 3.60; p = 0.012). Mortality was significantly greater in the DKA group (22.9% vs. 0%, risk difference 22.9%, 95% CI 8.4% to 37.4%; p = 0.003). CONCLUSION: In patients with T2DM and COVID-19, DKA was not characterized by absolute insulinopenia but was associated with older age, longer diabetes duration, severe insulin resistance, and systemic inflammation. These factors contribute to significantly increased morbidity and mortality. Our findings highlight the multifactorial nature of DKA in this setting and underscore the importance of aggressive monitoring and management in high-risk patients. CLINICAL TRIAL NUMBER : Not applicable. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13244619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148202177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated perspectives on vitamin D deficiency, screening, supplementation and clinical guidance. 维生素D缺乏的最新观点,筛查,补充和临床指导。
Pub Date : 2026-06-04 DOI: 10.1186/s40842-026-00300-9
Muhammad Ajmal Dina, Asif Hanif, Anam Arshed, Asifa Karamat, Muhammad Shakeel Basit, Muhammad Akram Bhutta, Muhammad Orangzaib Ehsan

Vitamin D functions like a hormone and plays a crucial role in regulating calcium levels and maintaining normal bone metabolism. A deficiency of vitamin D can lead to an increased risk of fractures, osteoporosis and osteomalacia that’s why research has linked vitamin D deficiency to various chronic diseases and certain types of cancer, thereby enhancing interest in its overall health implications. vitamin D deficiency is still prevalent among many populations. It is often found in older adults, individuals with chronic health conditions, those residing in care facilities and women who are either pregnant or nursing. There exists significant variability in clinical practices. Experts have differing opinions on who should undergo screening, what serum levels indicate sufficiency and the appropriate timing for initiating supplementation. This narrative review explores the key reservations that influence the diagnosis and management of vitamin D deficiency and current perspectives on screening, identifies high-risk populations that may benefit from testing and delineates circumstances in which empirical supplementation is a sensible and effective approach. Monitoring is beneficial and discusses how target levels correlate with bone health outcomes. A specific focus is directed towards the frequently cited 25(OH)D threshold of 30 ng/mL which is broadly linked to optimal bone health and underscores the synergistic significance of vitamin D and calcium in the management of osteoporosis and elucidates the reasons that why cholecalciferol is the favored formulation of vitamin D due to its advantageous pharmacological characteristics.

维生素D的功能就像一种激素,在调节钙水平和维持正常的骨代谢方面起着至关重要的作用。缺乏维生素D会导致骨折、骨质疏松和骨软化症的风险增加,这就是为什么研究将维生素D缺乏与各种慢性疾病和某些类型的癌症联系起来,从而增强了对其整体健康影响的兴趣。维生素D缺乏在许多人群中仍然很普遍。该病常见于老年人、慢性病患者、居住在护理机构的人以及孕妇或哺乳期妇女。在临床实践中存在显著的可变性。专家们对哪些人应该接受筛查、什么血清水平表明足够以及开始补充的适当时间有不同的意见。这篇叙述性综述探讨了影响维生素D缺乏症诊断和管理的关键保留意见,以及目前对筛查的看法,确定了可能从测试中受益的高危人群,并描述了经验补充是一种明智和有效方法的情况。监测是有益的,并讨论了目标水平如何与骨骼健康结果相关。一个特定的焦点指向经常被引用的25(OH)D阈值30 ng/mL,这与最佳骨骼健康广泛相关,强调了维生素D和钙在骨质疏松症管理中的协同作用,并阐明了为什么胆骨化醇是维生素D的首选配方,因为它具有有利的药理特性。
{"title":"Updated perspectives on vitamin D deficiency, screening, supplementation and clinical guidance.","authors":"Muhammad Ajmal Dina, Asif Hanif, Anam Arshed, Asifa Karamat, Muhammad Shakeel Basit, Muhammad Akram Bhutta, Muhammad Orangzaib Ehsan","doi":"10.1186/s40842-026-00300-9","DOIUrl":"10.1186/s40842-026-00300-9","url":null,"abstract":"<p><p>Vitamin D functions like a hormone and plays a crucial role in regulating calcium levels and maintaining normal bone metabolism. A deficiency of vitamin D can lead to an increased risk of fractures, osteoporosis and osteomalacia that’s why research has linked vitamin D deficiency to various chronic diseases and certain types of cancer, thereby enhancing interest in its overall health implications. vitamin D deficiency is still prevalent among many populations. It is often found in older adults, individuals with chronic health conditions, those residing in care facilities and women who are either pregnant or nursing. There exists significant variability in clinical practices. Experts have differing opinions on who should undergo screening, what serum levels indicate sufficiency and the appropriate timing for initiating supplementation. This narrative review explores the key reservations that influence the diagnosis and management of vitamin D deficiency and current perspectives on screening, identifies high-risk populations that may benefit from testing and delineates circumstances in which empirical supplementation is a sensible and effective approach. Monitoring is beneficial and discusses how target levels correlate with bone health outcomes. A specific focus is directed towards the frequently cited 25(OH)D threshold of 30 ng/mL which is broadly linked to optimal bone health and underscores the synergistic significance of vitamin D and calcium in the management of osteoporosis and elucidates the reasons that why cholecalciferol is the favored formulation of vitamin D due to its advantageous pharmacological characteristics.</p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13235093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148160454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of acylcarnitine species and diabetes incidence in a population-based apparently healthy cohort. 在以人群为基础的明显健康队列中酰基肉碱种类与糖尿病发病率的关系
Pub Date : 2026-06-01 DOI: 10.1186/s40842-026-00298-0
Ko Ko Maung, Rebecca Borreggine, Hector Gallart-Ayala, Julijana Ivanisevic, Pedro Marques-Vidal

BACKGROUND: Current diabetes risk scores often fail to detect early metabolic changes. Acylcarnitines species (ACs), intermediates of mitochondrial fatty acid oxidation, may indicate early dysregulation in diabetes, but prospective evidence is limited. We investigated the associations between circulating ACs and 10-year incidence of diabetes, and whether AC improve the predictive performance of established diabetes risk scores. METHODS: Data from 1,976 apparently healthy adults in a population-based cohort. Incident diabetes was defined as HbA1c ≥ 48 mmol/mol or initiation of glucose-lowering medication at follow-up. Associations were analysed using bivariate and multivariate models, and predictive value was assessed by adding ACs individually to FINDRISC, SDA, Kahn clinic, Kahn clinic+biologic, Wilson, Balkau and Griffin scores. RESULTS: Over 10 years, 35 participants developed diabetes. Higher baseline levels of Propionyl-, Isovaleryl-, Hexanoyl-, and Octenoylcarnitine were associated with incident diabetes in bivariate analysis whereas only Propionylcarnitine remained associated in multivariate analyses, mean ± sem 376.3 ± 2.7 vs. 419.1 ± 20.4 nmol/L in non-Diabetes and incident diabetes, respectively, p < 0.05. Sensitivity analyses using both diabetes and prediabetes incidence showed similar pattern of associations compared to the primary analysis. In predictive analyses, Propionyl- and Isovalerylcarnitine remained independently associated with incident diabetes after adjustment for each established diabetes risk scores. Adding Isovalerylcarnitine to the risk scores improved discrimination in three out of seven risk scores: AUC 0.785 (0.710–0.859), 0.841 (0.789–0.892), and 0.841 (0.789–0.892) for Balkau, SDA and FINRISK, respectively. CONCLUSION: Specific AC species, particularly Propionyl- and Isovalerylcarnitine, predicted 10-year risk of diabetes and improved predictive performance beyond established risk scores, suggesting their potential as early metabolic markers.

背景:目前的糖尿病风险评分往往不能检测早期代谢变化。酰基肉碱类(ACs),线粒体脂肪酸氧化的中间体,可能提示糖尿病的早期失调,但前瞻性证据有限。我们调查了循环ACs与10年糖尿病发病率之间的关系,以及AC是否提高了已建立的糖尿病风险评分的预测性能。方法:以人群为基础的队列研究,数据来自1976名明显健康的成年人。偶发性糖尿病定义为HbA1c≥48 mmol/mol或在随访时开始使用降糖药物。使用双变量和多变量模型分析相关性,并通过将ACs单独添加到FINDRISC、SDA、Kahn诊所、Kahn诊所+生物、Wilson、Balkau和Griffin评分中来评估预测价值。结果:在10年的时间里,35名参与者患上了糖尿病。在双变量分析中,较高的丙戊基-、异戊基-、己醇基-和辛烷基肉碱基线水平与糖尿病发病率相关,而在多变量分析中,只有丙戊基肉碱与糖尿病发病率相关,非糖尿病和糖尿病发病率的平均值分别为376.3±2.7和419.1±20.4 nmol/L, p
{"title":"Association of acylcarnitine species and diabetes incidence in a population-based apparently healthy cohort.","authors":"Ko Ko Maung, Rebecca Borreggine, Hector Gallart-Ayala, Julijana Ivanisevic, Pedro Marques-Vidal","doi":"10.1186/s40842-026-00298-0","DOIUrl":"10.1186/s40842-026-00298-0","url":null,"abstract":"<p><p>BACKGROUND: Current diabetes risk scores often fail to detect early metabolic changes. Acylcarnitines species (ACs), intermediates of mitochondrial fatty acid oxidation, may indicate early dysregulation in diabetes, but prospective evidence is limited. We investigated the associations between circulating ACs and 10-year incidence of diabetes, and whether AC improve the predictive performance of established diabetes risk scores. METHODS: Data from 1,976 apparently healthy adults in a population-based cohort. Incident diabetes was defined as HbA1c ≥ 48 mmol/mol or initiation of glucose-lowering medication at follow-up. Associations were analysed using bivariate and multivariate models, and predictive value was assessed by adding ACs individually to FINDRISC, SDA, Kahn clinic, Kahn clinic+biologic, Wilson, Balkau and Griffin scores. RESULTS: Over 10 years, 35 participants developed diabetes. Higher baseline levels of Propionyl-, Isovaleryl-, Hexanoyl-, and Octenoylcarnitine were associated with incident diabetes in bivariate analysis whereas only Propionylcarnitine remained associated in multivariate analyses, mean ± sem 376.3 ± 2.7 vs. 419.1 ± 20.4 nmol/L in non-Diabetes and incident diabetes, respectively, p < 0.05. Sensitivity analyses using both diabetes and prediabetes incidence showed similar pattern of associations compared to the primary analysis. In predictive analyses, Propionyl- and Isovalerylcarnitine remained independently associated with incident diabetes after adjustment for each established diabetes risk scores. Adding Isovalerylcarnitine to the risk scores improved discrimination in three out of seven risk scores: AUC 0.785 (0.710–0.859), 0.841 (0.789–0.892), and 0.841 (0.789–0.892) for Balkau, SDA and FINRISK, respectively. CONCLUSION: Specific AC species, particularly Propionyl- and Isovalerylcarnitine, predicted 10-year risk of diabetes and improved predictive performance beyond established risk scores, suggesting their potential as early metabolic markers. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13224560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sex-specific roles of insulin-like growth factor-1, lean mass and fat mass in type 2 diabetes prevention: Mendelian randomization studies in Western and East Asian populations. 胰岛素样生长因子-1、瘦质量和脂肪质量在2型糖尿病预防中的性别特异性作用:孟德尔随机研究在西方和东亚人群中
Pub Date : 2026-05-29 DOI: 10.1186/s40842-026-00285-5
Man Ki Kwok, Parco Ming Fai Siu, Shan Luo, Shiu Lun Au Yeung, Gabriel M Leung, Catherine Mary Schooling

BACKGROUND: Sex-specific effects of body composition and its drivers, including insulin-like growth factor-1 (IGF-1), on type 2 diabetes mellitus (T2DM) are understudied across ethnicity. We assessed the role of IGF-1 in T2DM and mediation by lean or fat mass, by sex in Western and East Asian populations, using Mendelian randomization (MR). METHODS: Genetic predictors of exposure (IGF-1) and mediators (fat or lean mass) were applied to genetic associations with T2DM in Europeans (n = 898,130) and East Asians (n = 433,540). Univariable and multivariable MR (MVMR) were used to obtain total and direct effects of IGF-1 and fat or lean mass on T2DM. Mediation analyses were conducted to obtain indirect effects. RESULTS: In the Western population, genetically predicted higher IGF-1 was positively associated with T2DM in women [odds ratio (OR) 1.21, 95% confidence interval (CI) 1.11 to 1.32] but not men, and in both sexes with lean mass but not fat mass. Lean mass in both sexes decreased and fat mass in women increased T2DM risk. In the East Asian population, genetically predicted higher IGF-1 was positively associated with T2DM in both sexes (1.07, 95% CI 1.02 to 1.12), and with lean mass and fat mass in men. Lean and fat mass were unrelated to T2DM. The association of IGF-1 with T2DM was not mediated by lean or fat mass. CONCLUSIONS: IGF-1 may directly increase T2DM risk, independent of body composition, in Western women and East Asians. Fat mass in women and less lean mass in both sexes may also increase T2DM risk in Western populations.

背景:身体成分及其驱动因素(包括胰岛素样生长因子-1 (IGF-1))对2型糖尿病(T2DM)的性别特异性影响在不同种族间尚未得到充分研究。我们使用孟德尔随机化(MR)评估了IGF-1在2型糖尿病中的作用,以及在西方和东亚人群中由瘦或脂肪量、性别所介导的作用。方法:将暴露的遗传预测因子(IGF-1)和介质(脂肪或瘦质量)应用于欧洲人(n = 898,130)和东亚人(n = 433,540)与T2DM的遗传关联。单变量和多变量MR (MVMR)用于获得IGF-1和脂肪或瘦质量对T2DM的总和直接影响。进行中介分析以获得间接影响。结果:在西方人群中,基因预测的较高的IGF-1与女性T2DM呈正相关[优势比(OR) 1.21, 95%可信区间(CI) 1.11至1.32],但与男性无关,并且在瘦体重而非肥胖体重的两性中都是如此。男性和女性的瘦体重减少,而女性的脂肪增加了患2型糖尿病的风险。在东亚人群中,基因预测较高的IGF-1与两性T2DM呈正相关(1.07,95% CI 1.02至1.12),与男性瘦体重和脂肪体重呈正相关。瘦肉和脂肪量与T2DM无关。IGF-1与T2DM的关联不受瘦或脂肪量的调节。结论:在西方和东亚女性中,IGF-1可能直接增加T2DM风险,与身体成分无关。在西方人群中,女性的脂肪量和男女的瘦肉量都可能增加2型糖尿病的风险。
{"title":"Sex-specific roles of insulin-like growth factor-1, lean mass and fat mass in type 2 diabetes prevention: Mendelian randomization studies in Western and East Asian populations.","authors":"Man Ki Kwok, Parco Ming Fai Siu, Shan Luo, Shiu Lun Au Yeung, Gabriel M Leung, Catherine Mary Schooling","doi":"10.1186/s40842-026-00285-5","DOIUrl":"10.1186/s40842-026-00285-5","url":null,"abstract":"<p><p>BACKGROUND: Sex-specific effects of body composition and its drivers, including insulin-like growth factor-1 (IGF-1), on type 2 diabetes mellitus (T2DM) are understudied across ethnicity. We assessed the role of IGF-1 in T2DM and mediation by lean or fat mass, by sex in Western and East Asian populations, using Mendelian randomization (MR). METHODS: Genetic predictors of exposure (IGF-1) and mediators (fat or lean mass) were applied to genetic associations with T2DM in Europeans (n = 898,130) and East Asians (n = 433,540). Univariable and multivariable MR (MVMR) were used to obtain total and direct effects of IGF-1 and fat or lean mass on T2DM. Mediation analyses were conducted to obtain indirect effects. RESULTS: In the Western population, genetically predicted higher IGF-1 was positively associated with T2DM in women [odds ratio (OR) 1.21, 95% confidence interval (CI) 1.11 to 1.32] but not men, and in both sexes with lean mass but not fat mass. Lean mass in both sexes decreased and fat mass in women increased T2DM risk. In the East Asian population, genetically predicted higher IGF-1 was positively associated with T2DM in both sexes (1.07, 95% CI 1.02 to 1.12), and with lean mass and fat mass in men. Lean and fat mass were unrelated to T2DM. The association of IGF-1 with T2DM was not mediated by lean or fat mass. CONCLUSIONS: IGF-1 may directly increase T2DM risk, independent of body composition, in Western women and East Asians. Fat mass in women and less lean mass in both sexes may also increase T2DM risk in Western populations. </p>","PeriodicalId":521069,"journal":{"name":"Cardiovascular diabetology. Endocrinology reports","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148059525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cardiovascular diabetology. Endocrinology reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
mjeditor
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1